Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,910,618)	$ (23,394,811)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	391,571	434,436
Issuance of convertible notes and preferred stock in legal settlement	0	9,000,000
Issuance of common stock, warrants and options for services	402,708	137,947
Extension of options issued to consultants	54,789	30,186
Extension of options issued to employees	36,990	105,802
Employee option cost	1,724,375	1,104,933
Common stock contributed to retirement plan	115,693	112,030
Impairment loss on abandonment of patents	37,352	0
Loss on retired equipment	9,016	2,828
Gain/loss on derivative instruments	(142,532)	(2,879,003)
Change in assets and liabilities:
Decrease (increase) in receivables	431,684	(414,126)
Decrease in deferred rent asset	450,374	468,030
Decrease (increase) in prepaid expenses	406,305	(1,991,596)
Decrease (increase) in inventory used for R&D and manufacturing	198,648	(102,026)
Decrease in accounts payable	(36,259)	(350,377)
(Decrease)/increase in accrued expenses	(96,513)	53,935
Increase in deferred revenue	1,500	0
Increase (decrease) in due to employees	3,443	(40,226)
Increase in deposits held	5,000	0
Decrease in deferred rent liability	(3,880)	(2,190)
Net cash used in operating activities	(8,920,354)	(17,724,228)
CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease in restricted cash	0	21,357
Purchases of equipment	(43,222)	(174,993)
Expenditures for Patent costs	(78,959)	(45,883)
NET CASH USED IN INVESTING ACTIVITIES	(122,181)	(199,519)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment for repurchase of preferred stock	0	(1,017,000)
Proceeds from issuance of common stock	14,289,518	0
Proceeds from exercise of warrants and stock options	2,664,539	604,588
Proceeds from sale of stock	0	2,343,994
Payments on convertible debt	(4,950,000)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	12,004,057	1,931,582
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	2,961,522	(15,992,165)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	4,260,594	26,568,243
CASH AND CASH EQUIVALENTS, END OF PERIOD	7,222,116	10,576,078
ISSUANCE OF WARRANTS:
Increase in derivative liabilities	(6,706,667)	0
Decrease in additional paid-in capital	6,706,667	0
Total	0	0
ISSUANCE OF ADDITIONAL SHARES
Increase in common stock	(8,333)	0
Increase in additional paid-in capital	(241,667)	0
Decrease in additional paid-in capital	250,000	0
Total	0	0
EXERCISE OF DERIVATIVE LIABILITIES:
Decrease in derivative liabilities	122,367	202,830
Increase in additional paid-in capital	(122,367)	(202,830)
Total	0	0
MODIFICATION OF WARRANTS:
Increase in additional paid-in capital	(325,620)	(1,068,369)
Decrease in additional paid-in capital	325,620	1,068,369
Total	0	0
INDUCEMENT WARRANTS:
Increase in additional paid-in capital	(1,593,000)	0
Decrease in additional paid-in capital	1,593,000	0
Total	0	0
ISSUANCE OF COMMON STOCK FOR PREPAID SERVICES:
Increase in additional paid-in capital	(141,333)	0
Increase in prepaid expenses	141,333	0
Total	0	0
PATENT COSTS INCLUDED IN ACCOUNTS PAYABLE
Increase in patent costs	0	93,553
Increase in accounts payable	0	(93,553)
Total	0	0
EQUIPMENT COSTS INCLUDED IN ACCOUNTS PAYABLE:
Increase in research and office equipment	0	33,705
Increase in accounts payable for Equipment costs	0	(33,705)
Total	0	0
DISMISSAL OF LIABILITY FOR OVERPAYMENT
Decrease in accrued expenses	0	81,395
Increase in additional paid-in-capital	0	(81,395)
Total	0	0
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash expenditures for interest expense	$ 336,316	$ 124,206